M&A transactions of medical devices
is our specialty

ConAlliance has outstanding M&A consulting expertise in projects in the "Medical Devices" segment.

Medical devices represent specialized segments within the healthcare industry. Each segment within medical technology is characterized by its unique technologies, intellectual property (IP), trends, regulations, and market dynamics. The complexity of these segments is illustrated by examples of specific applications of medical devices and technologies:

 

The more precisely M&A advisors grasp these specialties and nuances the more effectively they can guide the respective project. Accordingly, ConAlliance has formed specialized teams dedicated to the distinct challenges of various medical technology segments and sectors. These teams possess the essential technological and regulatory expertise, have a deep understanding of the markets, and stay informed about the latest market trends. And are investment banking and corporate finance experts at same times.

 

In this way, we distinguish ourselves as a consulting firm and ensure our expertise facilitates the swift execution of mandates, delivering the best possible outcomes in the context of transactions.

ConAlliance: Unparalleled healthcare insight driving exceptional deal outcomes.

Quickcontact

Cliff Murphy, MBA

Managing Director United Kingdom
+44 (20) 81 44 36 00
Curriculum vitae & references

Günter Carl Hober

Managing Partner
+49 (89) 809 53 63- 0
Curriculum vitae & references

Dr. Charlotte Rothmann

Head of the Americas
+1 (312) 38 00 85 0
Curriculum vitae & references

Prof. Christian Langbein, LLM

Partner
+49 (89) 809 53 63- 0
Curriculum vitae & references

Dipl.-Kfm. Martin Franz

Partner
+49 (89) 809 53 63- 0
Curriculum vitae & references

Prof. Dr. Dr. Ulrich Hemel

Partner
+49 (89) 809 53 63- 0
Curriculum vitae & references

Peer-Olof Andersen

Head of Scandinavia
+44 (20) 81 44 36 00
 

Gun-Woo Kim, MBA

Head of East-Asia
+852 8197 90 20
 

Masashi Asai

Head of Japan
+ 81 (50) 553931-00
 

Read also

Selected M&A transactions in the "Medical Devices" segment

  1. Medtronic's Acquisition of Mazor Robotics (2018). Strategic Rationale: This acquisition enhanced Medtronic's capabilities in robotic-assisted spinal surgery by combining Mazor's robotic systems with Medtronic's spinal implants and navigation platform. (Transaction value: $430 million)
  2. Boston Scientific's Acquisition of NxThera (2018). Strategic Rationale: This acquisition enabled Boston Scientific to expand its urology portfolio, particularly with the Rezūm System for treating benign prostatic hyperplasia (BPH). (Transaction value: $306 million)
  3. Teleflex's Acquisition of NeoTract (2017). Strategic Rationale: Teleflex expanded its urology segment with NeoTract's UroLift System, a minimally invasive treatment for BPH, thereby enhancing its product offerings in this growing market. (Transaction value: $325 million)
  4. Baxter's Acquisition of Seprafilm Adhesion Barrier from Sanofi (2020). Strategic Rationale: This acquisition strengthened Baxter's surgical portfolio with Seprafilm, a bioresorbable barrier to reduce postoperative adhesions. (Transaction value: $350 million)
  5. Hologic's Acquisition of Cynosure (2017). Strategic Rationale: Hologic expanded into the medical aesthetics market with Cynosure's portfolio of laser- and light-based aesthetic treatment systems. (Transaction value: $385 million)
  6. Stryker's Acquisition of K2M Group Holdings (2018). Strategic Rationale: This acquisition strengthened Stryker's spine division by incorporating K2M's minimally invasive solutions and complex spine technologies into its portfolio. (Transaction value: $500 million)
  7. Smith & Nephew's Acquisition of Ceterix Orthopaedics (2019). Strategic Rationale: Smith & Nephew acquired Ceterix to enhance its meniscus repair capabilities with the NovoStitch Pro Meniscal Repair System, addressing unmet clinical needs in knee surgeries. (Transaction value: $50 million)
  8. Thermo Fisher Scientific's Acquisition of Advanced Bioprocessing from BD (2018). Strategic Rationale: This acquisition complemented Thermo Fisher's bioproduction offerings by integrating Advanced Bioprocessing's cell culture media and supplements. (Transaction value: $477 million)
  9. 3M's Acquisition of M*Modal's Technology Business (2019). Strategic Rationale: This acquisition allowed 3M to integrate M*Modal's cloud-based conversational AI technology with its Health Information Systems, improving clinical documentation and workflows. (Transaction value: $430 million)
  10. Hill-Rom's Acquisition of Mortara Instrument (2017). Strategic Rationale: This acquisition expanded Hill-Rom's diagnostic cardiology business by adding Mortara's diagnostic cardiology and monitoring technologies. (Transaction value: $330 million)
  11. Stryker's Acquisition of OrthoSensor (2021). Strategic Rationale: This acquisition enhanced Stryker's capabilities in smart sensor technologies for orthopedic surgeries, particularly with OrthoSensor's intraoperative VERASENSE sensors. (Transaction value: Not disclosed, estimated under $500 million)
  12. Philips' Acquisition of Capsule Technologies (2021). Strategic Rationale: Although slightly above the threshold, this acquisition integrated Capsule's technologies for medical device integration and data processing into Philips' patient management solutions. (Transaction value: $635 million)
  13. Boston Scientific's Acquisition of Farapulse (2021). Strategic Rationale: This acquisition provided Boston Scientific with a novel pulsed field ablation technology for the treatment of atrial fibrillation. (Transaction value: $295 million)
  14. Zimmer Biomet's Acquisition of A&E Medical (2020). Strategic Rationale: This acquisition expanded Zimmer Biomet's portfolio in cardiothoracic surgery with A&E Medical's sternal closure devices and cable systems. (Transaction value: $250 million)
  15. Integra LifeSciences' Acquisition of ACell (2021). Strategic Rationale: Integra expanded its regenerative medicine portfolio with ACell's MatriStem UBM, a technology used in surgical and wound care applications. (Transaction value: $300 million)
  16. Hillrom's Acquisition of Bardy Diagnostics (2021). Strategic Rationale: This acquisition strengthened Hillrom's capabilities in advanced cardiac diagnostics with Bardy's CAM Patch technology for ambulatory cardiac monitoring. (Transaction value: $375 million)
  17. Smith+Nephew's Acquisition of Integra LifeSciences' Extremity Orthopedics Business (2021). Strategic Rationale: This acquisition expanded Smith+Nephew's portfolio in shoulder arthroplasty and foot and ankle surgery. (Transaction value: $240 million)
  18. Boston Scientific's Acquisition of Preventice Solutions (2021). Strategic Rationale: The acquisition added solutions for remote cardiac monitoring to Boston Scientific's product offerings. (Total transaction value: $925 million, including milestone payments; upfront payment under $500 million)
  19. Hologic's Acquisition of Biotheranostics (2021). Strategic Rationale: This acquisition strengthened Hologic's diagnostics portfolio with Biotheranostics' molecular diagnostic tests for breast and metastatic cancers. (Transaction value: $230 million)
  20. Teleflex's Acquisition of Z-Medica (2020). Strategic Rationale: This acquisition brought Z-Medica's hemostatic products, such as QuikClot, into Teleflex's portfolio for vascular and interventional access. (Transaction value: $500 million)

Quicklinks

Back to top
Find a contact person